Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/62914COMPARTIR / EXPORTAR:
 SHARE
 CORE
BASE
|
|
| Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
| Título: | Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders |
Autor: | Rawstron, Andy C.; Orfao, Alberto CSIC ORCID ; Mateo, Gema; Pérez-Andrés, Martin CSIC ORCID CVN; San Miguel, Jesús F. CSIC ORCID | Fecha de publicación: | 2008 | Editor: | Ferrata Storti Foundation | Citación: | Haematologica 93(3): 431-438 (2008) | Resumen: | The European Myeloma Network (EMN) organized two flow cytometry workshops. The first aimed to identify specific indications for flow cytometry in patients with monoclonal gammopathies, and consensus technical approaches through a questionnaire-based review of current practice in participating laboratories. The second aimed to resolve outstanding technical issues and develop a consensus approach to analysis of plasma cells. The primary clinical applications identified were: differential diagnosis of neoplastic plasma cell disorders from reactive plasmacytosis; identifying risk of progression in patients with MGUS and detecting minimal residual disease. A range of technical recommendations were identified, including: 1) CD38, CD138 and CD45 should all be included in at least one tube for plasma cell identification and enumeration. The primary gate should be based on CD38 vs. CD138 expression; 2) after treatment, clonality assessment is only likely to be informative when combined with immunophenotype to detect abnormal cells. Flow cytometry is suitable for demonstrating a stringent complete remission; 3) for detection of abnormal plasma cells, a minimal panel should include CD19 and CD56. A preferred panel would also include CD20, CD117, CD28 and CD27; 4) discrepancies between the percentage of plasma cells detected by flow cytometry and morphology are primarily related to sample quality and it is, therefore, important to determine that marrow elements are present in follow-up samples, particularly normal plasma cells in MRD negative cases. | Descripción: | This is an open access paper.-- et al. | URI: | http://hdl.handle.net/10261/62914 | DOI: | 10.3324/haematol.11080 | Identificadores: | doi: 10.3324/haematol.11080 issn: 0390-6078 e-issn: 1592-8721 |
| Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
| Fichero | Descripción | Tamaño | Formato | |
|---|---|---|---|---|
| Report of the European.pdf | 192,29 kB | Adobe PDF |  Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
145
checked on 13-abr-2024
SCOPUSTM
Citations
413
checked on 16-abr-2024
WEB OF SCIENCETM
Citations
352
checked on 29-feb-2024
Page view(s)
542
checked on 19-abr-2024
Download(s)
573
checked on 19-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.